文献速递肿瘤 PET/CT

68Ga-PSMA PET/CT 阳性淋巴结的体积形态学特征与前列腺癌肿瘤分化程度的分层关系

68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.
PubMed 文献 · J Nucl Med · 2017-06-21

回顾性分析147例生化复发前列腺癌患者的362枚68Ga-PSMA PET阳性淋巴结,按诊断时Gleason评分分为低、中、高分化三组,比较SUVmax及CT形态学尺寸。高GS组SUVmax最高,低GS组淋巴结短轴最小;按CT形态学标准仅34%低GS、56%中GS、53%高GS患者被判为CT阳性,68Ga-PSMA使90例(61%)患者从cN0重新分期为cN1。

要点

  • 68Ga-PSMA PET阳性淋巴结的SUVmax均值:低GS组13.5、中GS组12.4、高GS组17.8。
  • 68Ga-PSMA阳性淋巴结平均短轴:低GS组7.7 mm(n=113)、中GS组9.4 mm(n=122)、高GS组9.5 mm(n=127)。
  • 按CT形态学标准仅34%低GS、56%中GS、53%高GS患者为CT阳性,68Ga-PSMA使90例(61%)从cN0改为cN1。

核心结论

  • 68Ga-PSMA PET是生化复发前列腺癌患者N分期中有前景的方法。
  • 在各GS队列中,传统影像相比PSMA分子分期均低估了淋巴结受累。
  • 68Ga-PSMA PET/CT的灵敏度使生化复发背景下可更早检出亚厘米淋巴结转移。

研究设计与样本

  • 回顾性研究纳入147例前列腺癌生化复发患者(平均年龄68岁,范围44-87岁;平均PSA 5 ng/mL,范围0.25-294 ng/mL)。
  • 所有PET/CT图像于静脉注射68Ga-PSMA后60±10分钟采集(平均剂量176 MBq)。
  • 共识别362枚68Ga-PSMA PET阳性淋巴结,按原发诊断时组织病理学分为低GS(GS≤6,高分化)、中GS(GS=7,中分化)、高GS(GS≥8,低分化)三组。
  • 采用半自动淋巴结分割软件(Fraunhofer MEVIS)基于CT测量淋巴结体积、短轴径和长轴径,并与SUVmax比较。
  • SUVmax≥2.0视为PSMA阳性,短轴径≥8 mm视为形态学阳性。

主要发现

  • 低GS组平均SUVmax为13.5(95%CI 10.9-16.1),中GS组为12.4(95%CI 9.9-14.9),高GS组为17.8(95%CI 15.4-20.3)。
  • 低GS组68Ga-PSMA阳性淋巴结平均短轴径为7.7 mm(n=113),中GS组为9.4 mm(n=122),高GS组为9.5 mm(n=127)。
  • 基于CT形态学标准,低GS组仅34%患者、中GS组56%患者、高GS组53%患者被视为CT阳性。
  • 总体而言,68Ga-PSMA显像使90例患者(61%)的临床分期从cN0重新分类为cN1。

关键数值与推荐

  • PSMA阳性标准:68Ga-PSMA摄取SUVmax≥2.0。
  • 形态学阳性标准:淋巴结短轴径≥8 mm。
  • Gleason评分分层:低GS为GS≤6(高分化),中GS为GS=7(中分化),高GS为GS≥8(低分化)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a new method to detect early nodal metastases in patients with biochemical relapse of prostate cancer. In this retrospective investigation, the dimensions, volume, localization, and SUVmax of nodes identified by 68Ga-PSMA were correlated to their Gleason score (GS) at diagnosis. Methods: All PET/CT images were acquired 60 ± 10 min after intravenous injection of 68Ga-PSMA (mean dose, 176 MBq). In 147 prostate cancer patients (mean age, 68 y; range, 44-87 y) with prostate-specific antigen relapse (mean prostate-specific antigen level, 5 ng/mL; range, 0.25-294 ng/mL), 362 68Ga-PSMA PET-positive lymph nodes (LNs) were identified. These patients were classified on the basis of their histopathology at primary diagnosis into either low- (GS ≤ 6, well differentiated), intermediate- (GS = 7, moderately differentiated), or high-GS cohorts (GS ≥ 8, poorly differentiated prostate cancer). Using semiautomated LN segmentation software (Fraunhofer MEVIS), we measured node volume and short-axis dimensions (SADs) and long-axis dimensions based on CT and compared with the SUVmax Nodes demonstrating uptake of 68Ga-PSMA with an SUVmax of 2.0 or more were considered PSMA-positive, and nodes with an SAD of 8 mm or more were considered positive by morphologic criteria. Results: Mean SUVmax was 13.5 (95% confidence interval [CI], 10.9-16.1), 12.4 (95% CI, 9.9-14.9), and 17.8 (95% CI, 15.4-20.3) within the low-, intermediate-, and high-GS groups, respectively. The morphologic assessment of the 68Ga-PSMA-positive LN demonstrated that the low-GS cohort presented with smaller 68Ga-PSMA-positive LNs (mean SAD, 7.7 mm; n = 113), followed by intermediate- (mean SAD, 9.4 mm; n = 122) and high-GS cohorts (mean SAD, 9.5 mm; n = 127). On the basis of the CT morphology criteria, only 34% of low-GS patients, 56% of intermediate-GS patients, and 53% of high-GS patients were considered CT positive. Overall, 68Ga-PSMA imaging led to a reclassification of stage in 90 patients (61%) from cN0 to cN1 over CT. Conclusion:68Ga-PSMA PET is a promising modality in biochemical recurrent prostate cancer patients for N staging. Conventional imaging underestimates LN involvement compared with PSMA molecular staging score in each GS cohort. The sensitivity of 68Ga-PSMA PET/CT enables earlier detection of subcentimeter LN metastases in the biochemical recurrence setting.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Vinsensia M, Chyoke PL, Hadaschik B, et al. 68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. J Nucl Med. 2017. PMID: 28637799. doi:10.2967/jnumed.116.185033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。